Even though these modalities are still at an experimental level, targeting the dual immune role of TGF-β (inhibitory or enhancing) could lead to the development of innovative therapies for autoimmune thyroid diseases that are conditioned on the subtype and the distinct pathophysiology of the latter. This evidence concerns the gene TGFB1 and autoimmune thyroid disease.